ArticleNature2022
Super-enhancer hypermutation alters oncogene expression in B cell lymphoma.
Erratum issuedOpen access · greenAbstract read
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 87 papers.
0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed
26.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 150 citations in OpenAlex.
- Article
- Different primary thyroid B-cell lymphomas show overlapping mutation profiles, suggesting involvement of a common pathogenic process.Haematologica · 2026Article
- Article
- A bivalent molecular glue linking lysine acetyltransferases to oncogene-induced cell death.Cell · 2026Article
- From cell to disease: Regulatory networks and mechanisms of super‑enhancers in aging (Review).Molecular medicine reports · 2026Review
- Machine learning-driven investigation on liquid-liquid phase separation-related prognostic signature in diffuse large B-cell lymphoma.British journal of haematology · 2026Article
- Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study.Blood advances · 2026Observational
- Molecular Mechanisms of Diffuse Large B-Cell Lymphoma and the Complexities of Tumor Development.Saudi medical journal · 2026Review
- BCL2 promoter region mutations are an independent marker of BCL2 level in lymphoid malignancies.NPJ genomic medicine · 2026Article
- Article
- LCR-modules: a collection of workflows for cancer genome analysis.Bioinformatics (Oxford, England) · 2026Article
- Hi-C for genome-wide detection of enhancer-hijacking rearrangements in routine lymphoid cancer biopsies.Cell genomics · 2026Article
- Chronic lymphocytic leukemia withHemaSphere · 2026Article
- Molecular Pathogenesis and Therapeutic Response of Diffuse Large B Cell Lymphoma Genetic Subtypes.Annual review of cancer biology · 2026Article
- Effects and molecular mechanism of inhibiting p53 signaling pathway by NSUN4 on the resistance to BCL-2 inhibitor for diffuse large B-cell lymphoma.Clinical and experimental medicine · 2026Article
- Dynamics of circulating tumour DNA in relapsed/refractory diffuse large B-cell lymphoma patients.British journal of haematology · 2026Article
- Superenhancers shape the landscape and repair dynamics of transcription-associated DNA breaks in cancer.Science advances · 2026Article
- Enhancer-dependent gene regulation in space, time, and malignancies.International journal of cancer · 2026Review
- T follicular helper cells transiently unlock a plasticity state in germinal centre B cells during the humoral immune response.Nature cell biology · 2026Article
- Reprogramming tumor immunity through APOBEC3s-mediated mutagenesis: from genome instability to immune checkpoint interactions.Frontiers in immunology · 2026Review
27 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
16 authors at 4 institutions in 3 countries.
Elodie BalInstitute for Cancer Genetics, Columbia University, New York, NY, USA.
Rahul KumarInstitute for Cancer Genetics, Columbia University, New York, NY, USA.ORCID http://orcid.org/0000-0002-6927-5390
Mohammad HadigolCenter for Systems and Computational Biology, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ, USA.
Antony B HolmesInstitute for Cancer Genetics, Columbia University, New York, NY, USA.ORCID http://orcid.org/0000-0001-7559-2678
Laura K HiltonCentre for Lymphoid Cancer, BC Cancer Research Centre, Vancouver, British Columbia, Canada.ORCID http://orcid.org/0000-0002-6413-6586
Jui Wan LohCenter for Systems and Computational Biology, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ, USA.
Kostiantyn DrevalDepartment of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, British Columbia, Canada.
Jasper C H WongCentre for Lymphoid Cancer, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
Sofija VlasevskaInstitute for Cancer Genetics, Columbia University, New York, NY, USA.
Clarissa CorinaldesiInstitute for Cancer Genetics, Columbia University, New York, NY, USA.
Rajesh Kumar SoniProteomics and Macromolecular Crystallography Shared Resource, Columbia University, New York, NY, USA.
Katia BassoInstitute for Cancer Genetics, Columbia University, New York, NY, USA.
Ryan D MorinDepartment of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, British Columbia, Canada.ORCID http://orcid.org/0000-0003-2932-7800
Hossein KhiabanianCenter for Systems and Computational Biology, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ, USA.
Laura PasqualucciInstitute for Cancer Genetics, Columbia University, New York, NY, USA. lp171@cumc.columbia.edu.ORCID http://orcid.org/0000-0001-6819-7370
Riccardo Dalla-FaveraInstitute for Cancer Genetics, Columbia University, New York, NY, USA. rd10@cumc.columbia.edu.ORCID http://orcid.org/0000-0002-3502-8826
Cancer Genetics (United States) · USColumbia University Irving Medical Center · USRutgers, The State University of New Jersey · USSimon Fraser University · CA
Funding
Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3MTRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Tracie Saunders · 1997 to 2026
$94.5MPreclinical Models and Therapeutics CoreP01CA229100 · NCI · MAYO CLINIC ARIZONA · PI SCOTT, DAVID WILLIAM · 2018 to 2022
$10.2MFrom pathogenesis to new therapeutic targets in Diffuse Large B cell LymphomaR35CA210105 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Riccardo Dalla-Favera · 2016 to 2026
$10.0MRole of MLL2 Gene Inactivation in B cell Non Hodgkin LymphomaR01CA172492 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PASQUALUCCI, LAURA · 2013 to 2022
$3.6MEvolution and clinical impact of clonal hematopoiesis of indeterminate potential in breast tumor microenvironmentR01CA233662 · NCI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI GANESAN, SHRIDAR · 2019 to 2023
$3.2MNCI NIH HHS P01 CA229100NCI NIH HHS P30 CA013696NCI NIH HHS P30 CA072720NCI NIH HHS R01 CA172492NCI NIH HHS R01 CA233662NCI NIH HHS R35 CA210105
Abstract
Diffuse large B cell lymphoma (DLBCL) is the most common B cell non-Hodgkin lymphoma and remains incurable in around 40% of patients. Efforts to sequence the coding genome identified several genes and pathways that are altered in this disease, including potential therapeutic targets
Indexed as
Enhancer Elements, GeneticGene Expression Regulation, NeoplasticLymphoma, Large B-Cell, DiffuseMutationOncogenesDown-RegulationHumansPositive Regulatory Domain I-Binding Factor 1Proto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-bcl-6Receptors, CXCR4Receptors, GlucocorticoidRepressor ProteinsBCL2 protein, humanBCL6 protein, humanCXCR4 protein, humanNR3C1 protein, humanPositive Regulatory Domain I-Binding Factor 1PRDM1 protein, humanProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-bcl-6Receptors, CXCR4Receptors, GlucocorticoidRepressor Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.